Incyte Corporation (INCY)

Market Cap	20.16B
Revenue (ttm)	4.81B
Net Income (ttm)	1.19B
Shares Out	196.32M
EPS (ttm)	5.90
PE Ratio	17.40
Forward PE	13.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,906,345
Open	97.77
Previous Close	97.31
Day's Range	97.36 - 103.45
52-Week Range	53.56 - 109.28
Beta	0.81
Analysts	Buy
Price Target	94.94 (-7.55%)
Earnings Date	Feb 9, 2026

About INCY

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 4, 1993
• Employees: 2,617
• Stock Exchange: NASDAQ
• Ticker Symbol: INCY
• Website: https://www.incyte.com

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Analyst Summary

According to 21 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $94.94, which is a decrease of -7.55% from the latest price.

Price Target

$94.94

(-7.55% downside)

Analyst Consensus: Buy